3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Peritoneal Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Ductal Adenocarcinoma
1
Ovarian Neoplasms
1
Melanoma
1
Limited Stage Small Cell Lung Cancer
1
Glioblastoma
1
Fallopian Tube Neoplasms
1
Carcinoma, Renal Cell
1
Interventions
Paclitaxel
22
Bevacizumab
20
Carboplatin
19
liposomal doxorubicin
14
Specimen Handling
14
Magnetic Resonance Spectroscopy
13
olaparib
12
Topotecan
9
Gemcitabine
9
Biopsy
8
pembrolizumab
7
Taxes
6
Immunoglobulin G
6
Disulfides
6
niraparib
4
mirvetuximab soravtansine
4
cediranib
4
Doxorubicin
4
oregovomab
3
Nivolumab
3
Cyclophosphamide
3
sarilumab
2
rucaparib
2
cemiplimab
2
berzosertib
2
adavosertib
2
Oxaliplatin
2
Docetaxel
2
Cisplatin
2
Biosimilar Pharmaceuticals
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Fallopian Tube Neoplasms
×
Glucose
×
90 days
×
Clear all
NCT03740165
2026-05-04
KEYLYNK-001
Merck Sharp & Dohme LLC
Phase 3
Completed
1,367 enrolled
29 charts